See more : Promimic AB (publ) (PRO.ST) Income Statement Analysis – Financial Results
Complete financial analysis of Tarsus Pharmaceuticals, Inc. (TARS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Tarsus Pharmaceuticals, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- TalkPool AG (TALK.ST) Income Statement Analysis – Financial Results
- Manufatura de Brinquedos Estrela S.A. (ESTR4.SA) Income Statement Analysis – Financial Results
- Fanuc Corporation (FANUY) Income Statement Analysis – Financial Results
- United Parks & Resorts Inc. (PRKS) Income Statement Analysis – Financial Results
- ManTech International Corporation (MANT) Income Statement Analysis – Financial Results
Tarsus Pharmaceuticals, Inc. (TARS)
About Tarsus Pharmaceuticals, Inc.
Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic that is in Phase III for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. The company is also developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. In addition, the company develops lotilaner to address diseases across therapeutic categories in human medicine, including eye care, dermatology, and other diseases. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 17.45M | 25.82M | 57.03M | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 1.59M | 955.00K | 2.08M | 246.00K | 74.00K | 1.00K |
| Gross Profit | 15.85M | 24.86M | 54.95M | -246.00K | -74.00K | -1.00K |
| Gross Profit Ratio | 90.87% | 96.30% | 96.36% | 0.00% | 0.00% | 0.00% |
| Research & Development | 50.31M | 42.62M | 41.71M | 18.83M | 3.16M | 901.00K |
| General & Administrative | 0.00 | 44.95M | 25.40M | 8.17M | 1.14M | 449.00K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 108.70M | 44.95M | 25.40M | 8.17M | 1.14M | 449.00K |
| Other Expenses | 0.00 | 86.00K | -73.00K | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 159.01M | 87.57M | 67.11M | 27.00M | 4.30M | 1.35M |
| Cost & Expenses | 160.61M | 88.53M | 69.18M | 27.00M | 4.30M | 1.35M |
| Interest Income | 10.34M | 3.50M | 36.00K | 188.00K | 40.00K | 0.00 |
| Interest Expense | 3.35M | 2.20M | 0.00 | 188.00K | 40.00K | 0.00 |
| Depreciation & Amortization | 877.00K | 789.00K | 606.00K | 246.00K | 74.00K | 1.00K |
| EBITDA | -131.67M | -59.11M | -13.17M | -26.56M | -4.56M | -1.35M |
| EBITDA Ratio | -754.69% | -229.03% | -18.55% | 0.00% | 0.00% | 0.00% |
| Operating Income | -143.16M | -62.71M | -12.16M | -27.00M | -4.30M | -1.35M |
| Operating Income Ratio | -820.53% | -242.92% | -21.32% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 7.27M | 617.00K | -1.62M | 188.00K | -371.00K | 32.00K |
| Income Before Tax | -135.89M | -62.10M | -13.77M | -26.81M | -4.67M | -1.32M |
| Income Before Tax Ratio | -778.89% | -240.53% | -24.15% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -4.00K | 55.00K | 1.00K | 1.00K | 1.00K |
| Net Income | -135.89M | -62.09M | -13.83M | -26.81M | -4.67M | -1.32M |
| Net Income Ratio | -778.89% | -240.51% | -24.25% | 0.00% | 0.00% | 0.00% |
| EPS | -4.62 | -2.52 | -0.67 | -1.32 | -0.24 | -0.31 |
| EPS Diluted | -4.62 | -2.52 | -0.67 | -1.32 | -0.24 | -0.31 |
| Weighted Avg Shares Out | 29.38M | 24.62M | 20.55M | 20.32M | 19.51M | 4.29M |
| Weighted Avg Shares Out (Dil) | 29.38M | 24.62M | 20.55M | 20.32M | 19.51M | 4.29M |
Tarsus to Participate in Fireside Chat at UBS Virtual Ophthalmology Day 2024
IRVINE, Calif., Sept. 25, 2024 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced that...
Tarsus Pharmaceuticals: Unlocking Growth Potential With Eye Care Innovations
Tarsus Pharmaceuticals, Inc.'s Xdemvy, the first FDA-approved treatment for demodex blepharitis, has shown significant efficacy and rapid revenue growth, with $40.8M revenue in Q2 2024. The company is expanding its pipeline to target meibomian gland disease and rosacea, with promising...
Tarsus to Participate in Fireside Chat at the 2024 Wells Fargo Securities Healthcare Conference
IRVINE, Calif., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced that...
Tarsus Pharmaceuticals: Strong Execution In Eye Disease Treatment
Tarsus Pharma has a drug for Demodex blepharitis and multiple late-stage assets in its pipeline, including lotilaner for various formulations. The company has seen a 65% increase in stock value, with a $1 billion market opportunity in the initial addressable...
Tarsus Pharmaceuticals, Inc. (TARS) Q2 2024 Earnings Call Transcript
Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS ) Q2 2024 Earnings Conference Call August 8, 2024 4:30 PM ET Company Participants David Nakasone - Head, Investor Relations Bobby Azamian - Chairman and CEO Aziz Mottiwala - Chief Commercial Officer Jeff Farrow - Chief...
Tarsus Pharmaceuticals, Inc. (TARS) Reports Q2 Loss, Tops Revenue Estimates
Tarsus Pharmaceuticals, Inc. (TARS) came out with a quarterly loss of $0.88 per share versus the Zacks Consensus Estimate of a loss of $0.98. This compares to loss of $1.17 per share a year ago.
Tarsus to Report Second Quarter 2024 Financial Results on Thursday, August 8, 2024
IRVINE, Calif., July 29, 2024 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced that...
Tarsus to Participate in Upcoming Investor Conferences
IRVINE, Calif., May 29, 2024 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced that...
Tarsus to Participate in Fireside Chat at the 2024 Bank of America Healthcare Conference
IRVINE, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced that...
Tarsus Pharmaceuticals, Inc. (TARS) Q1 2024 Earnings Call Transcript
Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS ) Q1 2024 Earnings Conference Call May 8, 2024 4:30 PM ET Company Participants David Nakasone - Head of Investor Relations Bobby Azamian - Chief Executive Officer and Chairman Aziz Mottiwala - Chief Commercial Officer Jeff...
Source: https://incomestatements.info
Category: Stock Reports